Drug interactions
Dipyridamole + Ponatinib
Severity: Minor
Dipyridamole and Ponatinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ponatinib inhibits BCRP and P-gp in vitro, so it could increase dipyridamole exposure. Ponatinib itself carries bleeding and vascular occlusion risk, which may add to antiplatelet effects. The pharmacokinetic effect is predicted, not established.
What this interaction means in plain words
Dipyridamole and Ponatinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Dipyridamole belongs to Cardiovascular; Ponatinib belongs to Oncology.
Why it happens
Ponatinib inhibition of BCRP/P-gp may raise dipyridamole exposure.
What to do
Monitor for dipyridamole adverse effects such as hypotension and headache, and for bleeding during ponatinib therapy.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Dipyridamole and Ponatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Dipyridamole
- Dipyridamole + Riociguat Contraindicated
- Adenosine + Dipyridamole Major
- Betrixaban + Dipyridamole Major
- Dabigatran + Dipyridamole Major
- Dipyridamole + Regadenoson Major
- Dipyridamole + Venetoclax Major
Other interactions of Ponatinib
Frequently asked questions
Can I take Dipyridamole with Ponatinib?
MediHelp rates the interaction as minor. Dipyridamole and Ponatinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Ponatinib inhibits BCRP and P-gp in vitro, so it could increase dipyridamole exposure. Ponatinib itself carries bleeding and vascular occlusion risk, which may add to antiplatelet effects. The pharmacokinetic effect is predicted, not established.
How serious is the interaction between Dipyridamole and Ponatinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for dipyridamole adverse effects such as hypotension and headache, and for bleeding during ponatinib therapy.
What other medicines interact with Dipyridamole?
MediHelp also lists interactions of Dipyridamole with, for example, Riociguat, Adenosine, Betrixaban. The full list is on the Dipyridamole page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
